S.F. Holding (06936) recorded a revenue of 25.376 billion yuan in April for its express delivery logistics business, supply chain, and international business, an increase of 6.11% year-on-year.
Shunfeng Holdings (06936) announced that the company's total revenue from express logistics, supply chain, and international business in April 2026 was RMB 25.376 billion, an increase of 6.11% year-on-year.
S.F. Holding (06936) announced that the total revenue from its express delivery logistics, supply chain, and international business in April 2026 was RMB 25.376 billion, an increase of 6.11% year-on-year.
In terms of express delivery logistics business, the company has been promoting the "Activate Operation" mechanism since 2025, achieving high business volume growth and driving network capacity improvement and model optimization. To further optimize the business structure, the company launched the "Activate Operation" advanced mechanism in the third quarter of 2025, transitioning from scale-driven advancement to value-driven advancement, gradually dynamically adjusting market strategies to ensure high-quality business growth. Thanks to the effective implementation of operational strategies, the company's business structure continues to improve, with single ticket revenue in the express delivery logistics business seeing consecutive monthly increases, and operational income increasing by 2.12% year-on-year to RMB 18.385 billion.
Revenue from the supply chain and international business increased by 18.25% year-on-year to RMB 6.991 billion, with the momentum of the second growth curve continuing to be unleashed. The company is firmly advancing its "Asia Only, Global Coverage" strategy, relying on a global service network and a rich product portfolio to respond agilely to market changes and actively seize the strategic opportunities of Chinese companies going global, driving strong growth in international express delivery and cross-border e-commerce logistics, as well as international supply chain business revenue.
Related Articles

SIPAI HEALTH (00314) spent 273,000 Hong Kong dollars to repurchase 200,000 shares on May 19th.

Lupe Biological (02157): Fan Xinyu was elected as a supervisor of the board of supervisors.

PW MEDTECH (01358) spent HKD 21,000 on May 19 to buy back 18,000 shares.
SIPAI HEALTH (00314) spent 273,000 Hong Kong dollars to repurchase 200,000 shares on May 19th.

Lupe Biological (02157): Fan Xinyu was elected as a supervisor of the board of supervisors.

PW MEDTECH (01358) spent HKD 21,000 on May 19 to buy back 18,000 shares.






